TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Telephone Coaching on Physical Performance in a Physical Exercise Maintenance Program for Fallers Elderly Patients Living at Home

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient aged 65 and over~* Patient having a physiotherapy treatment~* Faller patient ( a fall in the preceding 12 months)~* patient leaving the service to return home or living at home~* Patient with a score ≥ 24/30 in the Mini Mental Status (MMS )~* patient able to get up a seat and walk 6 meters without human assistance (corresponds to test TUG ) patient~* informed of the study has given free and informed consent~Exclusion Criteria:~* Patient under judicial protection , under guardianship~* patient with active disease , with degenerative impact on walking,~* patient unable to use the phone~* patient with visual impairments preventing reading the physical maintenance program~* Refusal of patient participation~* Patient not wishing to stop his liberal physiotherapy care to driving~* Patient included in another interventional research protocol

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- telephone coaching (Type: EXPERIMENTAL): Patients randomized to the experimental group will benefit from the telephone coaching , with 5 phone calls programmed by the physiotherapist according to the most convenient times for the patient, due to appointments per month.~The telephone coaching conducted by the physiotherapist with patients is to assess the number of exercises performed, the number of falls may have occurred, assess the fear of falling and overall assessment of the patient's general condition and a self-assessment of their physical ability (one leg balance, fear of falling, FTSST). With this information, the therapist may encourage patients to practice more diligently exercises can even strengthen the practice of some based on its evaluation.~Data from the telephone coaching will be recorded in the eCRF.
- Without telephone coaching (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 19-85 years~* Planning of elective noncardiac surgery or invasive procedure~* At least 1 year interval between the surgery or procedure and last PCI with next generation DES~* Currently on antiplatelet therapy~Exclusion Criteria:~* PCI with BMS(bare metal stent), 1st generation DES or bioresorbable vascular scaffold~* Total length of inserted DES in the 3 vessels \>60 mm~* History of stent thrombosis~* History of coronary artery bypass grafting surgery~* Planned surgery or procedure with high bleeding risk including followings: intracranial neurosurgery, spinal canal surgery, and eye posterior chamber surgery, endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), ampullary resection, endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic sphincterotomy plus large-balloon papillary dilation, endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) of cystic lesions~* Left ventricular ejection fraction \<40%~* Myocardial infarction within 6 months~* Any overt thromboembolism requiring medical surveillance and/or treatment~* Any clinically overt sign of hemorrhage within 3 months~* Anticoagulant therapy for any reason~* Need of continuation or discontinuation of antiplatelet therapy during surgery or procedure at the discretion of cardiologist or operator~* Any contraindication, adverse drug reaction or hypersensitivity to aspirin~* Pregnant women or women with potential childbearing~* Inability to understand or read the informed content

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Continuing aspirin (Type: ACTIVE_COMPARATOR): Patients in the group may continue the administration of aspirin during perioperative period.
- Stopping aspirin (Type: EXPERIMENTAL): Patients in the group may stop medication of antiplatelet drugs during perioperative period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Reassessment Strategy in the Diagnosis of Coronary Heart Disease in Elderly

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients 75 of age or older hospitalized in a geriatric service and suspect of coronary heart disease~Exclusion Criteria:~* acute myocardial infarction

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Diagnosis strategy and subsequent therapeutic reassessment All patients are in that arms. They all receive the diagnosis reassessment strategy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of a Group Psychological Intervention in Reducing Self-stigma Among Patients With Mental Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Attend clinic every 2 weeks~* Willingness to attend all sessions~Exclusion Criteria:~* Cognitive impairment that limits the participant from understanding material and answering questions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: t

Study Arms:
- Group Psychological Intervention (Type: EXPERIMENTAL): One topic will be discussed at each of the six sessions using some principles from cognitive behavioral therapy and psychoeducation.
- Treatment-as-usual (Type: NO_INTERVENTION): Participants will receive their usual care which involves being seen by a mental health professional (psychologist, psychiatrist/resident in psychiatry, or mental health nurse).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~* Age ≥ 18 and \< 75, men and women;~* need of vasoactive agents to maintain SBP \> 90 mmHg or MAP \> 60 mmHg.~* Left ventricle systolic function ≤35%~* SCAI B-D according to CSWG definition (JACC 2022)~EXCLUSION CRITERIA~* septic shock with evident septic focus;~* severe peripheral vascular disease~* CS secondary to cardiac and non-cardiac surgery;~* Acute myocardial infarction within 1 month;~* Suspected or documented myocarditis~* Pulmonary embolism~* Chronic end-stage organ dysfunction that would preclude heart transplant/durable VAD~* ominous prognosis (life expectancy \< 1 year);~* any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial~* pregnant, lactating or women planning pregnancy during the course of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Early intra-aortic balloon pump (IABP) implantation (Type: ACTIVE_COMPARATOR): IABP implantation within 6 hours since cardiogenic shock symptoms onset
- Standard of care as vasoactive agent (Type: OTHER): Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Cough and Small Fiber Neuropathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~In diabetic patients with chronic cough:~* Chronic cough defined by cough for more than 8 weeks.~* Normal chest X-ray~* history of type 2 diabetes~* Age of diabetes onset\> 40 years~* Affiliated or beneficiary person of social security~* Free, informed and written consent~In diabetic patients without chronic cough~* History of type 2 diabetes~* Age of discovery of diabetes\> 40 years~* Affiliated or beneficiary person of social security~* Free, informed and written consent~Exclusion Criteria:~* Presence of physical signs of peripheral neuropathy~* Active smoking or smoking cessation within the last 12 months~* Pregnant or lactating woman~* History of non-type 2 diabetes (type I, secondary diabetes, monogenic ...)~* Cancer within the last 5 years (except cutaneous squamous cell carcinoma)~* History of anti-cancer chemotherapy~* Suspicion of autoimmune pathology~* Active neurological pathology~* Electromyography in favor of large fiber neuropathy~* Chronic pathology that may interfere with the neurophysiological assessment~* Patient who were given anticoagulation drug therapy, anti-cholinergic drugs, beta-blocker and impossibility to withdraw the treatment before neurophysiological tests~In diabetic patients without chronic cough, another non-inclusion criteria is acute or chronic cough

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diabetic patients with chronic cough (Type: OTHER): Diabetic patients with chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.
- Diabetic patients without chronic cough (Type: OTHER): Diabetic patients without chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post Traumatic Stress Among Relatives of Brain-dead, Withdrawal of Life Support, and Sudden Death Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants are the nearest relatives (or person-of-trust) of a patient who has passed away in an intensive care unit (ICU). The cause of death must fall into 1 of the following three categories: (1) brain death with multiple organ donation +/- tissues; (2) death via limitation and / or cessation of active treatment (LATA) without brain death; (3) sudden death of a previously healthy patient (no physical or mental limitations; MacCabe score = 0) within 3 days of admission to ICU without LATA nor brain death~* The participant must be one of the following (roman numerals indicate prioritization in choice of participants, if needed): (i) designated person-of-trust; (ii) spouse/partner of the deceased; (iii) parent of the deceased; (iv) child of the deceased; (v) sibling of the deceased.~Exclusion Criteria:~* Patient deceased after 3 days of ICU care without LATA~* The deceased was under 18 years old~* The deceased was over 70 years old~* Refusal to participated~* Participant does not speak French~* The participant is under judicial protection, under tutorship or curatorship~* The participant is deaf or mute~* The deceased has no nearest relative

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brain death with organ donation (Type: None): Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes brain death with multiple organ donation +/- tissues.
- Limitation/cessation of active treatment (Type: None): Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes limitation/cessation of active treatment without brain death.
- Sudden death (Type: None): Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death was sudden death of a previously healthy patient (no physical or mental limitations; MacCabe score = 0) within 3 days of admission to ICU without LATA nor brain death.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of erythematous skin lesion, consistent with erythema migrans (EM).~* Age 18 or older.~* Ability to read, comprehend, and sign the informed consent form.~* Two (2) or more signs/symptoms of Lyme Disease~Exclusion Criteria:~* Subject has medically diagnosed bleeding disorder.~* Having had taken antibiotics in the past 30 days.~* EM located on face or neck.~* Unable to provide consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EM present (Type: ACTIVE_COMPARATOR): All patients must display signs/symptoms of Lyme disease as well as exhibit an EM lesion.
- No EM present (Type: ACTIVE_COMPARATOR): All patients must display signs/symptoms of Lyme disease but do not have an EM lesion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mirror-Box Training in Adults With Chronic Hemiparesis Secondary to Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* First unilateral ischemic stroke resulting in hemiparesis at least 6 months prior to enrollment.~* Age at time of enrollment: 30-80 years.~* Voluntary informed consent of patient.~* Patient willing to comply with protocol and is available for all scheduled visits.~* Residual upper extremity hemiparesis.~* No changes in medications planned during 8-week participation.~* No other motor rehabilitative therapy during 8-week participation, including E-stim and acupuncture.~* At least 20 degrees of active wrist extension and 10 degrees of active finger extension against gravity in the affected upper limb, as measured by goniometry.~Exclusion Criteria:~* Serious cognitive deficits, as evidenced by score of \<20 on Modified Mini-Mental Status Exam~* Hemorrhagic or bilateral strokes~* Excessive spasticity at the elbow, wrist, or hand, defined as a Modified Ashworth Scale score of \>2~* History of botulinum toxin injection in affected upper extremity in the past 4 months~* Lacking \>40 degrees of passive elbow extension~* Less than 45 degrees of passive shoulder flexion~* Global or receptive aphasia present on physical exam~* Hemispatial neglect present on physical exam~* Patient participating in constraint-induced therapy during study time period~* Severe visual deficits or visual field deficits as determined by ability to ascertain number of fingers held up on visual field testing~* Deformity/amputation of unaffected upper limb

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Mirror training (Type: OTHER): Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same therapist who performed the pretests.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Decreasing Propofol Injection Pain by Pre-Treatment With Lidocaine in Pediatric Procedural Sedation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 2 months to 17 years~* patient already scheduled for procedural sedation with propofol~* sedation procedure to be performed by a sedationist from Children's Respiratory and Critical Care Specialists~Exclusion Criteria:~* patients who are not receiving deep sedation with propofol~* patients with allergy or other contraindication to lidocaine administration~* patients with central venous catheters as propofol does not burn when given centrally~* patients being premedicated with an analgesic other than nitrous oxide or 1% lidocaine~* patients weighing less than 5 kg to prevent any risk of inadvertent lidocaine overdose.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
- Normal Saline (Type: PLACEBO_COMPARATOR): Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Maastricht Neck Study: Cervical Range of Motion in Whiplash Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients have had a measurement of the cervical range of motion.~Exclusion Criteria:~* None.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Whiplash patients (Type: None): The cohort is based on 100 whiplash patients which underwent the measure procedure to obtain cervical range of motion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients with Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The participants in this study will be community dwelling, males with prostate cancer (PC) and their healthcare advocate, if applicable~* Proficiency in English is required~Exclusion Criteria:~* Mental incompetency to participate in the study and/or no treatment option due to other health reasons

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (AVCT) (Type: EXPERIMENTAL): Patients participate in an adaptive virtual consultation on trial.
- Arm 2 (non-AVCT) (Type: ACTIVE_COMPARATOR): Patients participate in a non-adaptive virtual consultation on trial.
- Arm 3 (information-only) (Type: ACTIVE_COMPARATOR): Patients receive information-only on trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MPS II Immunophenotyping

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject has a confirmed diagnosis of Mucopolysaccharidosis type II (MPS II) or Hunter Syndrome based on enzyme activity and variant analysis.~* Subject who plan to receive or have received enzyme replacement therapy with idursulfase.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Naive (Type: None): Subjects who are naïve to ERT and start treatment with idursulfase
- Treatment less than 3 years (Type: None): Subjects who have received ERT for \<3 years
- Treatment over 3 years (Type: None): Subjects who have received ERT for 3 or more years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues